| Document |
Document Title |
|
JP3048637B2 |
PCT No. PCT/EP91/02495 Sec. 371 Date Feb. 25, 1994 Sec. 102(e) Date Feb. 25, 1994 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11279 PCT Pub. Date Jul. 9, 1992.New D-homo-(16-ene)-11 beta -aryl-4-estrenes of general formula I (I) as well as...
|
|
JP2000506491A |
(57) [Summary] The present invention relates to the use of colored or fluorescent hepatobiliary-targeting compounds in the production of administrable compositions to facilitate visibility of bile duct and bile leakage during surgery in ...
|
|
JP3040175B2 |
The invention relates to novel sulphamate derivatives of 1,3,5(10)-estratriene derivatives of general formula (I) in which the 3-sulphamate group is acylated, sulphonated or amido-sulphonated. Also disclosed are methods of producing thes...
|
|
JP3037508B2 |
PURPOSE: To obtain a new substd. 16-methyl-steroid deriv. of pregna-1,4- diene-3,20-dione useful as an intermediate for the synthesis of 16-methylene steroid. CONSTITUTION: The substd. 16-methyl-steroid deriv. is a compd. of formula I [w...
|
|
JP3036141B2 |
PURPOSE: To provide the title novel compound having high nonlinear optical performance for wavelength transformation, etc., thus useful for nonlinear optical materials and nonlinear optical elements. CONSTITUTION: The objective compound ...
|
|
JP3037427B2 |
Starting compounds for preparing calcitriol (1$g(a), 25-dihydroxycholecalciferol) and its derivatives showing, as compared with calcitriol, some modifications, particularly in the C-17 lateral chain, a method for preparing these starting...
|
|
JP3032315B2 |
|
|
JP3031585B2 |
PURPOSE: To obtain a lyase enzyme inhibitor which contains specific aminosteroids and is useful as a treating agent for androgen and estrogen dependent diseases, such as prostatic cancers and prostatic hypertrophies. CONSTITUTION: This 1...
|
|
JP2000504025A |
The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithel...
|
|
JP2000503985A |
Novel potentiating steroid carbamates having the general formula (I) ST-OCONR1R2(I) wherein ST is a steroid or steroid derivative, of the structure (II) optionally containing double bonds and additional oxygen substituents; the carbamate...
|
|
JP3026997B2 |
New products (I): in which R1 denotes an aliphatic hydrocarbon radical (C1-8), Ra and Rb denote a hydrogen or an alkyl (C1-4), R2 denotes a hydrogen or an optionally substituted alkyl (C1-12), n denotes one of the values from 1 to 6, Z d...
|
|
JP3021651B2 |
The present invention is directed to 2 beta ,19-(methyleneamino)androst-4-ene-3,17-dione which has the formula and the corresponding 17 beta -ol which are useful as aromatase inhibitors. The compounds are prepared by the cyclization of a...
|
|
JP3021818B2 |
PURPOSE: To industirially advantageously obtain the compd. of the subject having 5α-reductase inhibiting activity for the treatment for acne and postatomegaly by allowing a 4,5-epoxy compd. of steroid to react with sodium azide in an in...
|
|
JP3021819B2 |
PURPOSE: To provide new compounds useful as 5α-reductase inhibitor for treating diseases mediated by dihydrotestosterone such as acne, benign prostatomegaly and male hormone type psilosis. CONSTITUTION: These compounds are expressed by ...
|
|
JP2000501732A |
Disclosed are steroid nitrite/nitrate ester derivatives of formula I: 1 wherein, the substituents are as defined in the specification and their use in the treatment of inflammatory diseases.
|
|
JP3010173B2 |
|
|
JP3009169B2 |
The invention relates to the compounds (I): in which A and B are either where R2 and R'2 are H or alkyl (C1-4), or where R3 is H or alkyl (C1-4) or acyl, and - either R17 and R'17 together form a ketone, - or R17 is hydroxyl or acyloxy a...
|
|
JP2000038392A |
To provide a novel compound that is useful as a linker for silicon base over a wide range of solid-phase syntheses, can be synthesized through a relatively simple process and can bond the ligand molecule to the solid-phase support before...
|
|
JP2999257B2 |
PCT No. PCT/EP91/01017 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18917 PCT Pub. Date Dec. 12, 1991.The invention includes compounds of the following formula where A and B either A...
|
|
JP2999258B2 |
PCT No. PCT/EP91/01018 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18918 PCT Pub. Date Dec. 12, 1991.A process for the production of 10 beta -H-11 beta -(substituted phenyl) steroid...
|
|
JP3000039B2 |
PCT No. PCT/DE91/00562 Sec. 371 Date Jun. 1, 1993 Sec. 102(e) Date Jun. 1, 1993 PCT Filed Jul. 5, 1991 PCT Pub. No. WO92/00991 PCT Pub. Date Jan. 23, 1992.The unsaturated 17 alpha -cyanomethyl-17 beta -hydroxy steroids of the formula I, ...
|
|
JP2990624B2 |
This invention provides N-long chain acyl neutral amino acid esters of the general formula (I) : wherein X represents an ester-forming residue of a sterol; COR represents a long chain acyl group having 8 to 22 carbon atoms; R<5> and R<6>...
|
|
JPH11308991A |
To economically obtain a steroid useful as a medicine or the like by incubating a sterol compound in the presence of protein(s) produced by a specific process under such conditions as to enable a steroid to be oxidized and the resulting ...
|
|
JP2963711B2 |
Genetically engineered host cells containing new expression cassettes are provided which are able to carry out biochemical oxidations of steroids. In particular the oxidation is carried out with cells into which DNA has been introduced w...
|
|
JP2961187B2 |
The invention relates to the products of the formula (I): …… in which:… R = alkyl, alkenyl, alkynyl or CN,… R1 = C1-6-alkyl which is unsubstituted or substituted by one or more radicals chosen from among C1-4-alkoxy or alkylthio,...
|
|
JP2959839B2 |
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified her...
|
|
JP2956776B2 |
There are provided 13-alkyl-11beta-phenyl-gonanes of formula I (I) wherein Z is an oxygen atom or N-OH; R2 is alpha- or beta-position methyl or ethyl; R1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, a...
|
|
JP2953725B2 |
A 11 beta -aryl-19-norprogesterone steroid of the formula: wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5 , wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl...
|
|
JP2947944B2 |
Compounds of the androstane series are described having general formulaand solvates thereof, in which R1 represents O, S or NH; R2 individually represents OC(=O)C1-6 alkyl; R3 individually represents hydrogen, methyl (which may be in eit...
|
|
JPH11509519A |
Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii)...
|
|
JP2927601B2 |
|
|
JPH11507929A |
Certain sterol derivatives, structurally related to natural compounds which can be extracted i.e. from bull testes and from human follicular fluid, can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
JPH11507815A |
The present invention provides novel phosphonic acid-based cationic lipids of the general structure:or a salt, or solvate, or enantiomers thereof wherein; (a) R1 is a lipophilic moiety; (b) R2 is a positively charged moiety; (c) R3 is a ...
|
|
JPH11507360A |
Several 19-nor-pregnanes are provided which have the capacity to neurochemically alter the hypothalamic function in an individual through nasal administration. These pharmaceutically active compounds can be administered by themselves or ...
|
|
JPH11507352A |
The present invention provides novel carbamate-based cationic lipids of the general structure: or a salt, or solvate, or enantiomers thereof wherein; (a) R1, is a lipophilic moiety; (b) R2 is a positively charged moiety; (c) n is an inte...
|
|
JP2911553B2 |
Compounds of the general formula I have been described in which X, R<1>, R<2>, R<3> and R<4> have the meaning stated in the description, as well as processes for the preparation thereof, pharmaceutical products containing these compounds...
|
|
JP2904310B2 |
The present invention relates to the compound of formula (I), (I) also known as 17 beta -N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5 alpha -androst-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparat...
|
|
JP2898417B2 |
Products of general formula (I): …… in which R denotes H, …… … … R1 and R2 denote alkyl or form with the nitrogen atom a 5 or 6-membered heterocyclic ring optionally containing another hetero atom or R denotes alkyl, alkoxy,...
|
|
JPH11505268A |
The invention relates to novel sulphamate derivatives of 1,3,5(10)-estratriene derivatives of general formula (I) in which the 3-sulphamate group is acylated, sulphonated or amido-sulphonated. Also disclosed are methods of producing thes...
|
|
JP2879703B2 |
This invention is directed to 4-substituted 17 beta -(cyclopropylamino)androst-5-en-3 beta -ol and related compounds and also to a method for using such compounds in the treatment of androgen-dependent disorders. The compounds are prepar...
|
|
JP2869684B2 |
|
|
JPH1160594A |
To provide the subject new derivative consisting of a specific bile acid derivative, having extremely high solubility in a solvent of an acidic pH region, giving little damage on the mucosa and useful as a nasal absorbefacient to improve...
|
|
JPH11502509A |
A therapeutic compound of the chlorambucil family conjugated to two or three acyl groups derived from fatty acids. The compound has the following formula.in which X is chlorambucil, Y is an optional spacer group, AA is an amino acid, B i...
|
|
JP2861262B2 |
|
|
JPH11500133A |
Certain benzopyran antiestrogens are disclosed for treating estrogen sensitive diseases such as breast cancer. Prodrug forms provide ease of manufacturing, good shelf life, and bioavailibility.
|
|
JP2834721B2 |
3-(Oxo or imino)-17 alpha -cyanomethylestra-4,9-diene 17 beta ethers and esters (I) are new: R1 = Me or Et; R2 = 1-10C alkyl, 1-10C acyl or trialkylsilyl; R3 = O or NOR; R = H; 1-10C acyl, 1-10C alkyl, sulphamoyl, or alkyl- or trialkylsi...
|
|
JP2837271B2 |
PCT No. PCT/DE90/00688 Sec. 371 Date Jul. 15, 1991 Sec. 102(e) Date Jul. 15, 1991 PCT Filed Sep. 6, 1990 PCT Pub. No. WO91/04265 PCT Pub. Date Apr. 4, 1991.A process for the production of progresterone derivatives of general formula I (I...
|
|
JP2831800B2 |
Herein are disclosed (1) an oil-soluble N-long chained acyl acidic amino acid mono- or di-ester having at least one sterol ester in the molecule of formula I, which is a novel compound of excellent emulsifying and hydrating performances,...
|
|
JP2828780B2 |
Novel substituted steroid compounds are disclosed which are more effective than known radical-trapping agents in methods of prophylaxis and therapy of radical-mediated cell damage and of treatment of diseases due to radical-mediated cell...
|
|
JPH10511958A |
The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5 alpha -reductase enzymes from 3-oxo-4-azasteroids having a 1,2-double bond and the...
|
